Product Images Terazosin Hydrochloride

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 5 images provide visual information about the product associated with Terazosin Hydrochloride NDC 49999-227 by Quality Care Products Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Image of Label - Terazosin5mgJubilant

Image of Label - Terazosin5mgJubilant

This is a description of a medication called Terazosin 5 MG Orange distributed by GEEGEL L. The medication is in capsule form and is sold in a bottle of 90 capsules. It is manufactured by Jubilant Cadista Pharmaceuticals Inc. and sold by 247 Medline Industries. It is important to store the medication at a controlled temperature between 68-77 degrees Fahrenheit, and to keep it out of children's reach. It is also recommended to consult with a physician or read the insert for dosage instructions.*

Chemical Structure - a00604ff 041d 4ad4 a3bb d0911bf0727e 01

Chemical Structure - a00604ff 041d 4ad4 a3bb d0911bf0727e 01

FIGURE 1 - a00604ff 041d 4ad4 a3bb d0911bf0727e 02

FIGURE 1 - a00604ff 041d 4ad4 a3bb d0911bf0727e 02

This appears to be a table or figure from a scientific study. It presents data on the mean change in total symptom score and mean increase in peak flow rate (mL/sec) from baseline for participants who received terazosin compared to a placebo group. The information on baseline values is located in an above table. The asterisk indicates a statistically significant difference (p < 0.05) between the terazosin group and the placebo group.*

FIGURE 2 - a00604ff 041d 4ad4 a3bb d0911bf0727e 03

FIGURE 2 - a00604ff 041d 4ad4 a3bb d0911bf0727e 03

This is a graph showing the mean change in total symptom score from baseline over time in a long-term, open-label, non-placebo controlled study involving 494 participants. The graph displays months 0 through 30, with significant improvement seen at 3 to 30 months. The mean baseline score was 10.7 and there is a significant reduction in symptoms compared to baseline.*

FIGURE 3 - a00604ff 041d 4ad4 a3bb d0911bf0727e 04

FIGURE 3 - a00604ff 041d 4ad4 a3bb d0911bf0727e 04

The text describes a figure labeled as "Figure 3" that shows the mean change in peak flow rate from baseline in an open-label, non-placebo controlled study. The figure includes a line graph with the mean change from baseline (in msec) plotted against time (ranging from month 0 to month 30). The graph notes that there was a statistically significant change from baseline (p<0.05), and that the mean baseline was 99.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.